Stockscreener 앱 받기
588.34
1.43%
-8.51
시간 외 거래:
591.00
2.66
+0.45%
전일 마감가:
$596.85
열려 있는:
$586.85
하루 거래량:
655.86K
Relative Volume:
0.61
시가총액:
$62.45B
수익:
$14.09B
순이익/손실:
$4.50B
주가수익비율:
14.98
EPS:
39.28
순현금흐름:
$2.96B
1주 성능:
-1.01%
1개월 성능:
+0.08%
6개월 성능:
-20.28%
1년 성능:
-40.00%
1일 변동 폭
$582.37
$591.64
1주일 범위
$582.37
$617.52
52주 변동 폭
$520.50
$1,211.20
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
Regeneron’s SWOT analysis: biotech giant faces eylea challenges, pipeline promise - Investing.com
Worldquant Millennium Advisors LLC Sells 15,966 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Woodline Partners LP Buys 3,862 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Css LLC Il Invests $435,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Victrix Investment Advisors Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
2,300 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Soleus Capital Management L.P. - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
1,038 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Novem Group - MarketBeat
Toronto Dominion Bank Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Does the 23andMe Acquisition Make Regeneron a Buy Now? - AOL.com
Does the 23andMe Acquisition Make Regeneron a Buy Now? - The Motley Fool
Two Sigma Investments LP Buys 12,154 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
212,128 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Voloridge Investment Management LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat
ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology - insights.citeline.com
Regeneron Initial Data on Multiple Myeloma Drug Encouraging - Yahoo Finance
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $890.60 - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports Promising Results In LINKER-MM2 Trial For Linvoseltamab - simplywall.st
Zurich Insurance Group Ltd FI Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Tidal Investments LLC - MarketBeat
USS Investment Management Ltd Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bayer wins EU recommendation for label expansion of Regeneron-partnered Eylea - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Vident Advisory LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Williams Jones Wealth Management LLC. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Jacobs Levy Equity Management Inc. - MarketBeat
Royal Bank of Canada Acquires 27,497 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.
Quantinno Capital Management LP Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Janus Henderson Group PLC Sells 84,661 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Strive Asset Management LLC Invests $419,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to acquire bankrupt genetic testing firm 23andMe for US$256 million - Proactive Investors
Litigators of the Week: A $406.8M Win for Regeneron in Antitrust Trial Showdown With Cholesterol Drug Rival Amgen - Law.com
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
Regeneron Pharmaceuticals Reveals Trial Data of Drug Combination to Treat Multiple Myeloma - marketscreener.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Lifted by Scientech Research LLC - MarketBeat
Regeneron (REGN) Reports Promising Trial Results for Linvoseltamab in Multiple Myeloma | REGN Stock News - GuruFocus
Breakthrough: Regeneron's Multiple Myeloma Drug Shows 90% Response Rate in New Combination Therapy Trial - Stock Titan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer - MSN
Bayer wins China approval for high-dose Eylea (REGN:NASDAQ) - Seeking Alpha
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewswire
Regeneron Enters into Agreement to Acquire Consumer Genetics Business - thehudsonindependent.com
Pathstone Holdings LLC Sells 1,254 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to buy 23andMe for $256M in court-supervised sale - MSN
1,064 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Sig Brokerage LP - MarketBeat
ProShare Advisors LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Man Group plc Sells 24,377 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sherbrooke Park Advisers LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Raiffeisen Bank International AG Invests $3.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Teza Capital Management LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Vestal Point Capital LP Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - AOL.com
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.26%
자본화:
|
볼륨(24시간):